Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-3713afe50f1010dc6d3a525f7492a818"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-3713afe50f1010dc6d3a525f7492a818"/>
<resource>
<Composition>
<id value="composition-en-3713afe50f1010dc6d3a525f7492a818"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-3713afe50f1010dc6d3a525f7492a818"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-3713afe50f1010dc6d3a525f7492a818</b></p><a name="composition-en-3713afe50f1010dc6d3a525f7492a818"> </a><a name="hccomposition-en-3713afe50f1010dc6d3a525f7492a818"> </a><a name="composition-en-3713afe50f1010dc6d3a525f7492a818-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1471/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - idefirix</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1471/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp3713afe50f1010dc6d3a525f7492a818"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - idefirix"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Idefirix is and what it is used for</li><li>What you need to know before you are given Idefirix</li><li>How to use Idefirix</li><li>Possible side effects</li><li>How to store Idefirix</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What idefirix is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What idefirix is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Idefirix contains the active substance imlifidase, which belongs to a group of medicines called immunosuppressants. It is given before your kidney transplantation to prevent the immune system (your body's defences) from rejecting the donated kidney.</p><p>Idefirix works by breaking down a type of antibody in the body called immunoglobulin G (IgG), which is involved in destroying 'foreign' or harmful substances.</p><p>Imlifidase is a protein from a bacterium called Streptococcus pyogenes.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take idefirix"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take idefirix"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You must not be given Idefirix</p><ul><li>If you are allergic to imlifidase or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have a severe infection.</li><li>If you have a blood disorder called thrombotic thrombocytopenic purpura (TTP), that results in blood clots forming in small blood vessels throughout the body.</li></ul><p>Warnings and precautions</p><p>Infusion reactions Idefirix contains a protein and it can cause allergic reactions in some people. You will receive medicines to reduce the risk of an allergic reaction. If you get any symptoms of an allergic reaction, such as severe rash, shortness of breath, feeling hot, flushing, during the infusion ( drip ), the infusion may need to be slowed down or stopped. When these symptoms go away, or improve, the infusion can be continued.</p><p>Infections IgG is important for protecting you against infections and since Idefirix breaks down IgG, you will receive antibiotics to reduce the risk of infections.</p><p>Antibody-mediated rejection (AMR)<br/>Your body will produce new IgG antibodies, which may attack the transplanted kidney. Your doctor will monitor you closely and you will receive medicines to reduce the risk of rejection.</p><p>Children and adolescents Do not give this medicine to children and adolescents under 18 years of age because it has not been studied in this age group.</p><p>Other medicines and Idefirix Tell your doctor if you are using, have recently used or might use any other medicines. Idefirix can affect the way some medicines work, and the dose of these may have to be adjusted.</p><p>As Idefirix breaks down IgG, IgG-based medicines may not work if given at the same time as Idefirix. This includes the following medicines:</p><ul><li>basiliximab (used to prevent rejection of kidney transplants)</li><li>rituximab (used to treat cancers such as non-Hodgkin s lymphoma and chronic lymphocytic leukaemia and inflammatory diseases such as rheumatoid arthritis)</li><li>alemtuzumab (used to treat a form of multiple sclerosis)</li><li>adalimumab (used to treat inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn s disease and ulcerative colitis)</li><li>denosumab (used to treat osteoporosis)</li><li>belatacept (used to prevent rejection of kidney transplants)</li><li>etanercept (used to treat inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis)</li><li>rabbit anti-thymocyte globulin (rATG) (used to prevent rejection of kidney transplants)</li><li>intravenous immunoglobulin (IVIg) (used to increase abnormally low immunoglobulin levels in the blood or to treat inflammatory diseases such as Guillain-Barr syndrome, Kawasaki disease and chronic inflammatory demyelinating polyneuropathy).</li></ul><p>Pregnancy and breast-feeding Idefirix is not recommended during pregnancy. Talk to your doctor if you think you may be pregnant.</p><p>It is not known whether Idefirix passes into breast milk. You should not breast-feed if you are being treated with Idefirix.</p><p>Idefirix contains sodium<br/>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take idefirix"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take idefirix"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Idefirix will be prescribed by a doctor with experience in kidney transplantation and it is for use in a hospital. The medicine will be given by infusion into your vein over about 15 minutes.</p><p>A healthcare professional will calculate the right dose for you based on your weight. Idefirix is usually given as a single dose, but your doctor may decide to give a second dose before the transplantation.</p><p>Information for healthcare professionals on dose calculation, preparation and infusion of Idefirix is given at the end of this leaflet.</p><p>If you receive more Idefirix than you should During and after the infusion you will be closely monitored. Healthcare professionals will check for any side effects.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you notice any of the following:</p><ul><li>Signs of infection, such as fever, chills, cough, feeling weak or generally unwell (very common</li><li>may affect more than 1 in 10 people).</li><li>Signs of an infusion reaction, such as severe rash, shortness of breath, feeling hot, flushing (common - may affect up to 1 in 10 people).</li><li>Muscle pain or fatigue (symptoms of myalgia) (common - may affect up to 1 in 10 people).</li></ul><p>Other side effects include:</p><p>Common (may affect up to 1 in 10 people):</p><ul><li>Infections: lung infection (pneumonia), infections of the blood (sepsis), abdominal infection, upper respiratory tract infection, adenovirus infection, parvovirus infection, urinary tract infection, influenza, wound infection, post-operative wound infection, catheter site infection</li><li>Transplant rejection (IgG antibodies will try to reject your donor kidney and you can feel general discomfort)</li><li>High or low blood pressure (symptoms of low blood pressure can be dizziness and symptoms of high blood pressure can be headache)</li><li>Low number of red blood cells (anaemia)</li><li>Dizziness at change of body position, e.g. when standing up</li><li>Headache</li><li>Burst blood vessel in the eye</li><li>Decreased vision</li><li>Increased heart rate</li><li>Infusion site pain</li><li>Increased liver enzymes (seen in blood tests)</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store idefirix"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store idefirix"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Idefirix is stored in the hospital pharmacy.</p><p>Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2-8 C). Do not freeze. Store in the original package in order to protect from light.</p><p>Chemical and physical in-use stability after reconstitution and dilution has been demonstrated for 24 hours at 2-8 C and for 4 hours at 25 C during this period.</p><p>Do not use this medicine if you notice particulate matter or discolouration after reconstitution.</p><p>Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Idefirix contains</p><ul><li>The active substance is imlifidase. Each vial contains 11 mg imlifidase. After reconstitution, each mL of concentrate contains 10 mg imlifidase.</li><li>The other ingredients are mannitol, polysorbate 80, trometamol, disodium edetate dihydrate and hydrochloric acid (for pH adjustment). See section 2 Idefirix contains sodium .</li></ul><p>What Idefirix looks like and contents of the pack</p><ul><li>Idefirix is supplied as a glass vial containing a powder for concentrate for solution for infusion (powder for concentrate). The powder is a white freeze-dried cake.</li><li>Packs contain 1 or 2 vials.</li></ul><p>Marketing Authorisation Holder<br/>Hansa Biopharma AB<br/>P.O. Box 220 07 Lund<br/>Sweden</p><p>Manufacturer Biotechnologines farmacijos centras Biotechpharma UAB Mokslininku street 4 LT-08412 Vilnius Lithuania</p><p>Propharma Group The Netherlands B.V. Schipholweg 2316 ZL, Leiden Netherlands</p><p>This leaflet was last revised in</p><p>This medicine has been given conditional approval . This means that there is more evidence to come about this medicine.<br/>The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp3713afe50f1010dc6d3a525f7492a818"/>
<resource>
<MedicinalProductDefinition>
<id value="mp3713afe50f1010dc6d3a525f7492a818"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp3713afe50f1010dc6d3a525f7492a818"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp3713afe50f1010dc6d3a525f7492a818</b></p><a name="mp3713afe50f1010dc6d3a525f7492a818"> </a><a name="hcmp3713afe50f1010dc6d3a525f7492a818"> </a><a name="mp3713afe50f1010dc6d3a525f7492a818-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/20/1471/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Idefirix 11 mg powder for concentrate for solution for infusion</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/20/1471/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Idefirix 11 mg powder for concentrate for solution for infusion"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
